Plaque Psoriasis Treatments: BMS-986165 Promising & Adalimumab Biosimilar Demonstrates Equivalence

References

1. Bristol-Myers Squibb. News release: Bristol-Myers Squibb’s novel, oral, selective TYK2 inhibitor delivered significant skin clearance in patients with moderate to severe plaque psoriasis in phase 2 trial. 2018 Sep 12.
2. Boehringer Ingelheim. News release: Biosimilar Cyltezo demonstrates clinical equivalence to Humira in patients with moderate to severe plaque psoriasis. 2018 Sep 12.
3. Boehringer Ingelheim. Efficacy, safety and immunogenicity of BI695501 vs. Humira in patients with moderate to severe chronic plaque psoriasis. ClinicalTrials.gov. 2018 May 23.